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Abstract Biocompatible poly-[N-(2-hydroxyethyl)-D,L-
aspartamide]-methoxypoly(ethyleneglycol)-hexadecylamine
(PHEA-mPEG-C16) conjugated with 1,4,7,10-tetraazacycl-
ododecan-1,4,7,10-tetraacetic acid-gadolinium (DOTA-Gd)
via ethylenediamine (ED) was synthesized as a magnetic
resonance imaging (MRI) contrast agent. Amphiphilic
PHEA-mPEG-C16-ED-DOTA-Gd forms micelle in aque-
ous solution. All the synthesized materials were charac-
terized by proton nuclear magnetic resonance (
1H NMR).
Micelle size and shape were examined by dynamic light
scattering (DLS) and atomic force microscopy (AFM).
Micelles with PHEA-mPEG-C16-ED-DOTA-Gd showed
higher relaxivities than the commercially available gado-
linium contrast agent. Moreover, the signal intensity of a
rabbit liver was effectively increased after intravenous
injection of PHEA-mPEG-C16-ED-DOTA-Gd.
Keywords MRI contrast agent   PHEA derivatives  
Micelles   Nanoparticles   Gd contrast agent
Introduction
Magnetic resonance imaging (MRI) is one of the most
impressive non-invasive imaging modality for diagnosis
[1, 2]. MRI is based on the nuclear magnetic resonance
(NMR) signal generated by hydrogen nuclei of water mol-
ecules and its changes that are dependent on the water dis-
tribution in tissues. MRI contrast agents improve diagnostic
accuracy by providing physiological information along with
the exquisitely high anatomic detail [3, 4]. In general, con-
trast agents consist of a paramagnetic metal center, typically
gadolinium(III),whichmustbechelatedwithanappropriate
ligand molecule, since the free metal ions are toxic at
quantity required for diagnosis [5, 6]. Gd(III) diethylene-
triaminepentaacetic acid (Gd(III)DTPA) and Gd(III) 1,4,
7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid (Gd
(III)DOTA)areclinicallyusedascontrastagentsduetotheir
thermodynamicstability [7].AmongGd-chelatecomplexes,
it has been known that the Gd-DOTA complex has much
greater stability than Gd-DTPA in physiological conditions.
The half-life of Gd-DOTA is estimated to be over
1,000 years at pH 7.4 [8, 9]. However, these low molecular
weightcontrastagentscannotdistinguisheffectivelydisease
tissues from normal tissues [10]. In recent years, contrast
agents with improved characteristics, such as increased
efﬁcacy and organ speciﬁcity, have been developed.
Several approaches to slow the rotational motion of
gadolinium-based contrast agents and thus to improve their
relaxation efﬁciency have been reported in the literature.
Macromolecular Gd complexes have been developed by
conjugating these Gd chelates to biocompatible polymer
such as dendrimers [11], linear polymers [12–14], or pro-
teins [15, 16] for exhibition of more effective relaxation as
well as prolongation of their intravascular retention time
[17]. For these purposes, various hydrophobic groups have
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tion of monoacid tetraester DTPA derivatives. The para-
magnetic complexes of these compounds have been studied
for the detection of tumors and myocardinal infections. In
addition, incorporation of certain amphiphilic gadolin-
ium(III) complexes into liposomes showed enhanced pro-
ton relaxibility [18, 19].
Another interesting strategy for the development of new
types of macromolecular contrast reagents is the synthesis
of amphiphilic gadolinium(III) complexes that can form
spontaneously micelles [20, 21]. We recently synthesized
biocompatible amphiphilic derivatives of DOTA with
hydrophobic alkyl chains, whose gadolinium(III) were
incorporated into DOTA of micelles. The resulting
micelles showed an increase in relaxibility relative to
DOTA-Gd (Omniscan
 ) because of the lower mobility of
the paramagnetic complex inside micelles.
Polymeric micelles very promising for MRI contrast
agents. Because the polymeric micelles is an associate of
many block copolymer chains, block copolymers with well-
controlled molecular weight can be excreted through kidney
ﬁltration after dissociation of the polymeric micelles into
block copolymer chains. Therefore, a low risk of chronic
toxicity is expected to present itself and is expected to stem
from polymeric micelles complete excretion over a long
time period. In addition, micelles are known to mimic the
phospholipid structure of the membranes and hence can be
good candidates as hepatocyte-speciﬁc agents [22].
Polyhydroxyethylaspartamide (PHEA) is a synthetic
polymer having protein-like structure, obtained by the
reaction of ethanolamine with polysuccinimide (PSI), itself
prepared by thermal polycondensation of D,L-aspartic acid.
PHEA has good biopharmaceutical properties as drug
carrier such as high water solubility, multifunctionality,
and low cost of production [23–29].
In this paper, we synthesized amphiphilic graft deriva-
tives of PHEA by the introduction of hydrophobic hexa-
decylamine (C16) and using ethylenediamine (ED) as a
linker of DOTA-Gd. DOTA was conjugated to PHEA-
mPEG-C16-ED, and then Gd was chelated to the PHEA-
mPEG-C16-ED-DOTA. MR contrast enhancing ability of
PHEA-mPEG-C16-ED-DOTA-Gd was investigated in vitro
and in vivo. The synthesized graft amphiphilic copolymers
have demonstrated to form polymeric micelles in aqueous
solution with 180 nm.
Experimental
Materials
Polysuccinimide (Baypure DSP
 , PSI, 8,190 g/mol)
was purchased from Lanxess Co., Ltd, Germany.
Methoxypoly(ethylene glycol)-amine [mPEG-NH2, number-
average molecular weight (Mn) & 5,000] was purchased
from SunBio Inc., Korea. 1-Hexadecylamine (C16–NH2),
gadolinium chloride hexahydrate (GdCl3•6H2O), N-(3-
dimethylaminopropyl)-N0-ethylcarbodiimide (EDC), and
N-hydroxysuccinimide (NHS) were purchased from
Sigma–Aldrich. N,N-Dimethylformamide (DMF), acetoni-
trile, and diethyl ether were commercially available and
were used without further puriﬁcation. Tri-sodium-DOTA
was obtained form Parish Chemical Company, Utah, USA.
Omniscan
  was purchased from Guerbet Co., Germany.
The in vivo contrast effect was performed in normal,
healthy New Zealand white rabbits weighing 3.0 kg. The
rabbits are anesthetized with an intramuscular injection of
Ketalar (ketamine hydrochloride, Yuhan, Seoul, Korea)
50 mg/kg and Rompun (xylazine hydrochloride, Bayer
Korea, Seoul, Korea) 5 mg/kg. The ﬁnal products were
administered into a marginal vein with 26G-needle syringe.
Synthesis of PHEA-mPEG-C16-ED-(DOTA-Gd)
A solution of mPEG-NH2 (0.3 g, 6 9 10
-5 mol) in DMF
(10 mL) was added dropwise to a solution of PSI (10 g,
1.22 9 10
-4 mol) in DMF (25 mL). The mixture was
stirred at 60 C under a nitrogen atmosphere. After 24 h, the
reaction solution was precipitated and ﬁltered with diethyl
ether for removal of DMF and unreacted materials. The
ﬁltered PSI-mPEG was washed with diethyl ether and dried
under vacuum. A solution of hydrophobic ligand, hexa-
decylamine (1.6 g, 6.7 9 10
-3 mol) in DMF (10 mL) was
dropped to a solution of PSI-mPEG (10 g, 4.76 9 10
-4
mol) in DMF (25 mL). The mixture was stirred at 60 C
under a nitrogen atmosphere. After 7 h, the reaction solu-
tion was precipitated and ﬁltered with diethyl ether. The
ﬁltered PSI-mPEG-C16 was washed with diethyl ether and
dried under vacuum.
A solution of ED (0.5749 g, 9.56 9 10
-3 mol) in DMF
(15 mL) was added dropwise to a solution of PSI-mPEG-
C16 (0.21 g, 8.97 9 10
-6 mol) in DMF (3 mL) at 40 C for
6 h. The prepared PHEA-mPEG-C16-ED was washed with
diethyl ether and then dried under vacuum at 30 C. The
resultant powder was dissolved in distilled water (10 mL)
and dialyzed against distilled water with dialysis mem-
brane (MWCO: 3,500) for 3 days to remove unreacted
monomers. The powder of PHEA-mPEG-C16-ED was
obtained after lyophilization.
DOTA (0.7 g, 1.5 9 10
-3 mol) was conjugated to
PHEA-mPEG-C16-ED (6.75 g, 2.5 9 10
-4 mol) using
EDC (3 9 10
-3 mol) and NHS (3 9 10
-3 mol) at ambient
temperature for 3 h. After reaction, the solution was dia-
lyzed and lyophilized. Dried PHEA-mPEG-C16-ED-DOTA
(6.87 g, 2.5 9 10
-4 mol) was dissolved in distilled water
again and GdCl3 (0.6 g, 1.5 9 10
-3 mol) was added in this
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123solution and stirred for 3 h. The prepared PHEA-mPEG-
C16-ED-DOTA-Gd was precipitated by acetonitrile,
washed with diethyl ether, and then dried under vacuum at
30 C for 6 h.
Characterization Analysis
The molecular weight of PSI, PSI-mPEG, PSI-mPEG-C16,
PSI-mPEG-C16-ED was conﬁrmed by GPC (PL-GPC220,
Polymer Laboratory, England) analysis. GPC had
two columns (10 lm, MIXED-Bx2. 50 nm), and DMF
(Aldrich) was used as mobile phase. The results of syn-
thesis were conﬁrmed by
1H NMR (Bruker 300, 500 MHz).
Dimethyl sulfoxide (DMSO, Aldrich) was used as solvent.
The size of micelles was assessed using an electrophoretic
light scattering spectrophotometer (ELS 8000, Otsuka
Electronics, Osaka, Japan) with 90  scattering angles at
25 C. The concentration of the samples was 2.5 mg/mL in
distilled water. Atomic force microscope (AFM) mea-
surements were carried out in the tapping mode with a
Nanoscope IV instrument to conﬁrm the shape of micelles.
The elemental analyses for C, H, and N were carried out on
elemental analyzer (Fisons EA-1108, Fisons, Italy). For
energy dispersive X-ray analysis (EDS, Quantax 200,
Bruker, Germany), samples were coated with carbon in
carbon coating unit and measurements were carried out at
20 kV at high vacuum. To determine gadolinium content,
samples were dissolved in 1% nitric acid, and the amount
of gadolinium in the solution was determined by induc-
tively coupled plasma emission spectrometer (ICP-AES,
iCAP 6,000 Series, Thermo Scientiﬁc, USA).
In Vitro and In Vivo MRI Test
To conﬁrm the feasibility of PSI-mPEG-C16-ED-DOTA-Gd
asMRIcontrastagent,weﬁrstpreparedPSI-mPEG-C16-ED-
DOTA-Gd solution and a commercially available Omni-
scan
  with varying Gd concentration from 1.0 9 10
-3 to
3.9 9 10
-6 M in distilled water. The T1-weighted MR
images of liver were performed with a turbo spin echo
technique. The sequence parameters were 9.6 ms of repeti-
tion time (TR), 4.6 ms of echo time (TE), 1 mm thickness,
and 256 m ﬁeld of view (FOV).
To get MR images of hepatic contrast enhancement,
PHEA-mPEG-C16-ED-DOTA-Gd or Omniscan
  (DOTA-
Gd solution) was administrated intravenously to rabbits
Fig. 1 Scheme for synthesis of PHEA-mPEG-C16-ED-DOTA-Gd
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123weighing 3.0 kg at a dose of 0.05 mmol Gd/kg. MR images
were taken before enhancement and 5, 10, 20, and 30 min
after intravenous administration. Phagocytosis of PHEA-
mPEG-C16-ED-DOTA-Gd micelles by hepatic Kupffer
cells was studied using electron microscopic analysis of the
liver tissue. The liver tissue was taken out from the killed
rabbits, ﬁxed with glutaraldehyde, and incubated with
osmium tetroxide (OsO4). In vitro and in vivo MR imaging
test were performed with a 3.0-T MRI system (Intera
Achieva 3.0T, Philips Medical Systems, Best, Philips Co.,
the Netherlands).
Results and Discussion
Synthesis and Characterization of PHEA-mPEG-C16-
ED-(DOTA-Gd)
To prepare the micelle-formed MRI contrast agent with
Gd, hydrophilic (mPEG) and hydrophobic moieties
(hexadecylamine) were conjugated with the PHEA back-
bone. PEG chains, being exposed to the external aqueous
phase, enhance water solubility of micelles and allow for
escaping the phagocytic systems as already reported in
various nanoparticle systems. On the other side, the hexa-
decylamine residues can form the micellar core to stabilize
nanoparticles. Finally, PHEA-mPEG-C16-ED-(DOTA-Gd)
has been prepared by the conjugation of DOTA-Gd via
ethylenediamine on the backbone chains of PHEA.
PSI-mPEG and PSI-mPEG-C16, PHEA-mPEG-C16-ED
were sequentially synthesized (28). The overall synthetic
route of PSI-mPEG-C16-ED is shown in Fig. 1.
1H-NMR
of PSI-mPEG, PSI-mPEG-C16, and PSI-mPEG-C16-ED are
shown in Fig. 1a–c, respectively.
1H-NMR analysis revealed a peak at 3.5 ppm that cor-
responds to –(OCH2CH2)n– of PEG chains and peaks at 0.8
and 1.3 ppm assigned, respectively, to -CH2CH3 and
–CH2–CH2–CH2– that belong to linked C16.
PHEA(polyhydroxyethyl aspartamide)-mPEG-C16-ED
was prepared from PSI-mPEG-C16 via ring-opening reac-
tion with ethylenediamine).
1H-NMR analysis revealed a
peak at 1.3 and 2.4 ppm assigned, respectively, to -CH2–
CH2- and –NH2 that belong to linked ED. Table 1 shows
weighted average molecular weights of the synthesized
copolymers determined by GPC. The average molecular
weight of PSI, PSI-mPEG, PSI-mPEG-C16, and PSI-
mPEG-C16-ED were 8,190, 21,000, 23,400, and 27,000,
respectively.
The degree of derivatization (DD) of each polymers in
terms of PEG and C16 content was evaluated by
1H-NMR
by comparing the integral of the peak corresponding to
PEG or hexadecylamine groups with the integral of the
peak assigned to PSI according to a procedure reported
elsewhere. The DD values in PSI-mPEG and PSI-mPEG-
C16 were reported in Table 1.
DOTA was conjugated to PHEA-mPEG-C16-ED using
EDC/NHS, and then Gd was chelated to PHEA-mPEG-
C16-ED-DOTA. Gd in PHEA-mPEG-C16-ED-DOTA-Gd
was conﬁrmed by EDS analysis (Fig. 2). Table 2 showed
Table 1 Main physico-chemical properties of PSI, PSI-mPEG, PSI-
mPEG-C16, and PHEA-mPEG-C16-ED
Sample Mw (kDa) mPEG DD
(mol %)
C16 DD
(mol %)
Yield
(%)
PSI 8,190 – –
PSI-mPEG 21,000 2 – 92
PSI-mPEG-C16 23,400 2 10 88
PHEA-mPEG-C16-ED 27,000 2 10 82
Fig. 2 EDS spectrum of PHEA-mPEG-C16-ED-DOTA (left) and PHEA-mPEG-C16-ED-DOTA-Gd (right)
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123that content of C, H, and N was decreased after incorpo-
ration of Gd. The average diameter of prepared micellar
PHEA-mPEG-C16-ED-DOTA was 180 nm from the data
of ELS and AFM (Fig. 3). That size is suitable for uptake
in liver.
The Enhancement Effect of PHEA-mPEG-C16-ED-
DOTA-Gd on MRI
T1-weighted MRI images of phantom are showed in Fig. 4.
The signal intensity increased more obviously in phantom
prepared with PHEA-mPEG-C16-ED-DOTA-Gd, in com-
parison with phantom prepared with Omniscan
 . Image
contrast showed similar patterns. These results showed that
prepared sample had better contrast imaging in smaller
amount more than Omniscan
 . The reason seems that
DOTA-Gd on PHEA backbone is aggregated closely.
Figure 5 shows the T1-weighted MRI images of a rabbit
before and at various time points after injection of the con-
trastagentpreparedwithPHEA-mPEG-C16-ED-DOTA-Gd.
This result showed a profound positive enhancement of the
liver after injection of PHEA-mPEG-C16-ED-DOTA-Gd.
We conﬁrmed that the prepared PHEA-mPEG-C16-ED-
DOTA-Gd contrast agent remarkably enhanced the normal
liver on T1-weighted MR image. The signal intensity was
started increasing 5 min after injection and gradually
increasedup to10 min.Thesignalintensityof blood vessels
gradually decreased over time, but signiﬁcant contrast
enhancement was still visible 30 min after injection. The
result indicates that PHEA-mPEG-C16-ED-DOTA-Gd can
be used as good contrast agent in lower concentration of Gd
and imaged for a long time or at request. Additionally,
PHEA-mPEG-C16-ED-DOTA-Gd complex seems to be
usedasbloodpoolcontrastagentduetohighsignalintensity
of blood vessel 30 min after intravenous administration.
Electron microscopic observation of the hepatic Kupffer
cells showed that phagocytosis of PHEA-mPEG-C16-ED-
DOTA-Gdbylysosomeswasmuchgreatercomparedtothat
of Omniscan
 .
Electron microscopic observation of the hepatic Kupffer
cells showed that phagocytosis of PHEA-mPEG-C16-ED-
DOTA-Gd by lysosomes was much greater compared to
that of Omniscan
  (Fig. 6).
Conclusion
In this study, we synthesized a biocompatible polymer
PHEA-mPEG-C16-ED and prepared micellar MRI contrast
agent by the conjugation of DOTA-Gd via ethylenediamine
Table 2 Elemental analysis of complex
Complex Element Elemental
analysis
average (%)
PHEA-mPEG-C16-ED-DOTA Nitrogen (N) 12.3244
Carbon (C) 44.7608
Hydrogen (H) 5.4125
PHEA-mPEG-C16-ED-DOTA-Gd Nitrogen (N) 5.1074
Carbon (C) 22.1675
Hydrogen (H) 2.6459
Fig. 3 a ELS data and b AFM image of PHEA-mPEG-C16-ED
micelles; average size, 180 nm
Concentration (M)
Omniscan
®
PHEA-mPEG-C16-ED-DOTA-Gd
Fig. 4 T1-weighted MR phantom image of PHEA-mPEG-C16-ED-
DOTA-Gd and Omniscan
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diameter was 180 nm, the suitable size as contrast agent for
liver enhancement.
Prepared PHEA-mPEG-C16-ED-DOTA-Gd when com-
pared with Omniscan
  showed better imaging contrast in
lower concentration of Gd from in vitro test. When solution
of PHEA-mPEG-C16-ED-DOTA-Gd was intravenously
injected into a rabbit, the T1-weighted image of the liver in
a rabbit was obviously enhanced and showed prolonged
intravascular duration time of about 30 min.
In summary, the newly developed PHEA-mPEG-C16-
ED-DOTA-Gd, a kind of micellar MRI contrast agent, had
biocompatible and good in vivo MRI imaging, compared to
commercial contrast agent. These results indicated PHEA-
mPEG-C16-ED-DOTA-Gd complex could be considered as
the MRI contrast agent for the detection of liver lesion.
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